Background: Gastric cancer (GC) is the fourth leading cause of cancer-related deaths, often diagnosed in late stages of the disease, limiting treatment options [1-2]. The absence of new therapies and proper diagnosis calls for an exploration of different potential targets. Epitranscriptomics studies RNA chemical modifications such as N6-methyladenosine (m6A), lately studied to understand its effect on cancer pr...